Navigation Links
Revolutionary drug could be new hope for adrenal cancer patients
Date:9/22/2009

SCOTTSDALE, Ariz. (Sept. 22, 2009) TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.

TCRS is a strategic alliance between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.

Other than surgery, the only treatment for ACC is the exacting use of a compound called mitotane, a chemical relative of DDT, which the U.S. banned as an insecticide in 1972.

TCRS clinicians hope the new compound, OSI-906, developed by OSI Pharmaceuticals Inc. of Melville, N.Y., will stop ACC tumor growth perhaps even promote tumor shrinkage without the toxic side effects of current chemotherapies. The trial will focus on patients with inoperable tumors who have relapsed or failed to respond to conventional therapies.

This clinical trial of OSI-906 is expected to last several years and include 135 patients, with 30-40 enrolled at TCRS. As there is no standard therapy available, two-thirds of the patients will receive the drug OSI-906 while one-third receives a placebo. Sites elsewhere in the U.S., as well as in Europe and Australia, are expected to enroll patients over the coming months.

"The trial is major step toward helping patients with ACC, who often face radical surgery as part of their treatment," says Dr. Michael J. Demeure, who will oversee the trial locally. Dr. Demeure is a TGen Senior Investigator and a Scottsdale Healthcare surgeon experienced in removing ACC tumors.

"It's a big operation requiring a large incision because these tumors can be the size of a football. Unfortunately many patients' tumors have spread so we can't remove it all, so new treatments are needed.'' said Dr. Demeure. "This unique partnership between Scottsdale Healthcare and TGen allows us to bring the newest and most promising treatments to pat
'/>"/>

Contact: Keith Jones
kjones@shc.org
480-882-4412
Scottsdale Healthcare
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Old developmental pathways spawn revolutionary evolutionary changes
2. M2SYS Introduces Revolutionary Biometric Artificial Intelligence Technology to Significantly Reduce Fingerprint Software False Reject Rates
3. Revolutionary CO2 maps zoom in on greenhouse gas sources
4. Revolutionary chefs? Not likely, shows physics research
5. Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy
6. Clemson chemists present revolutionary teaching concepts
7. A revolutionary new model for Alzheimers disease
8. New advance in revolutionary bullet fingerprinting technique
9. Newly created cancer stem cells could aid breast cancer research
10. Obesity and lack of exercise could enhance the risk of pancreatic cancer
11. Finding that 1-in-a-billion that could lead to disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Revolutionary drug could be new hope for adrenal cancer patients
(Date:7/29/2014)... some good news for parents of preterm babies latest ... by the time they become teenagers, the brains of many ... at term. , A study conducted by the University,s ... the preterm child experiences no brain injury in early life, ... good as their term-born peers. , However, the results of ...
(Date:7/29/2014)... it affects 1 in 100,000 people characterized by ... its cause remains unknown, a new study by a team ... Bonn in Germany and other European institutions confirms for the ... published on 6 July in Nature Genetics , is ... we swallow, a sphincter in the lower esophagus opens, allowing ...
(Date:7/29/2014)... A new study from UC San Francisco is the ... stressors accumulate overtime and accelerate cellular aging, these negative ... exercising and sleeping well. , "The study participants ... telomere shortening than the ones who didn,t maintain healthy ... said lead author Eli Puterman, PhD, assistant professor in ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2Mysterious esophagus disease is autoimmune after all 2Healthy lifestyle may buffer against stress-related cell aging, study says 2
... breathing problems after birth, and rare, inherited DNA differences may ... Medicine in St. Louis. The study is the first ... associated with a significant number of cases of respiratory distress ... RDS is the most common respiratory problem in newborns and ...
... Putnam Valley, NY. (Nov. 27, 2012) A ... Cell Transplantation (21:8), now freely available on-line ... mesenchymal cells derived from skeletal muscle (SM-MSCs) or ... muscle (myocardium) of separate groups of laboratory rats ...
... scientists from the University of Navarra and the Catalan Association ... Maestrazgo caves in Teruel, Spain. Their description has been published ... to one of the most ancient animal species on the ... a region of the Iberian Range where fauna has not ...
Cached Biology News:Gene linked to respiratory distress in babies 2Gene linked to respiratory distress in babies 3Study suggests different organ-derived stem cell injections improve heart function 2Three new arthropod species have been found in the Maestrazgo Caves in Teruel 2
(Date:7/29/2014)... WARRINGTON, Pa. , July 29, 2014 /PRNewswire/ ... company dedicated to advancing a new standard of ... financial results on August 5, 2014 before the ... The Company will host a live teleconference ... day. During the conference call, Discovery Labs, management ...
(Date:7/29/2014)... , July 29, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, applauds the ... taking a strong position in opposition to current ... 27, 2014 publication.  The New York Times also ... this week exploring the issue called "High Time:  ...
(Date:7/29/2014)... PA & Rockville, MD (PRWEB) July 29, 2014 ... Therapeutics, Inc. (ITI), a vaccine pioneer in the ... financial services firm Newport Coast Securities, Inc. to ... ITI is commercializing LAMP-vax technology, a breakthrough vaccine ... vaccines and immunotherapy market. The company exclusively licensed ...
(Date:7/29/2014)... 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... its investment in Green Chemistry and donated more than ... year, the Company announced Monday in its new ... World? The report comes in a ... a responsible corporate citizen, including recognition for the second ...
Breaking Biology Technology:Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... 2011 Landauer, Inc. (NYSE: LDR ... monitoring and the leading domestic provider of outsourced medical physics ... quarter ended March 31, 2011.   Fiscal 2011 ... to $32.3 million on contribution from Medical Physics segment and ...
... N.J., May 3, 2011 BioNeutral Group, Inc. ... today announced that it has signed on to ... disinfectant technology to the infection control professionals attending ... in Infection Control and Epidemiology) ( www.apic.org ). ...
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company dedicated to ... financial results for the first quarter ended March 31, 2011. ... 2011, VIVUS reported a net loss of $9.9 million or $0.12 ... or $0.23 per share for the first quarter of 2010. The ...
Cached Biology Technology:Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 2BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 3BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 4VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
ATGL Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Human sIL-2R/CD25 ELI-PAIR Kit...
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
Biology Products: